Gilead Sciences Aktie News

Gilead Sciences and Arcus Biosciences said on Friday they would stop a late-stage study testing their experimental cancer drug combination in patients with advanced stomach and esophageal cancers after it failed to show a survival benefit.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation awards $3M in grants to close gaps in education, care, and support for people living with metastatic breast cancer.

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL), even among those ineligible for the previous standard of care, high-dose chemotherapy followed by an autologous ste...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), presented Phase 1 data today with encouraging efficacy and safety results for its two investigational bicistronic CAR T-cell therapies, KITE-753 and KITE-363, respectively, in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL). The results of the analysis were shared in an oral presentation (Abstract #...

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), and its partner Arcellx, today announced new positive data from its pivotal iMMagine-1 Phase 2 study of anitocabtagene autoleucel (anito-cel), an investigational agent, which continues to show clinically meaningful deep and durable efficacy with predictable and manageable safety observed to date in relapsed or refract...

Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript

Gilead Sciences, Inc. (GILD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

Gilead Sciences remains a bullish pick, with raised guidance and strong Q3/25 results, driving optimism for continued growth. Gilead Sciences key growth drivers, include robust sales from Livdelzi and Yeztugo, alongside patent protection for Biktarvy until 2036. Despite a higher P/FCF ratio, Gilead Sciences is still undervalued, with an intrinsic value estimate of $146.12, supporting its invest...